Novartis Says FDA Deems Pluvicto Shortage Resolved, Supply Set to Increase Into 2024
October 27 2023 - 12:45AM
Dow Jones News
By Giulia Petroni
Novartis said that the U.S. Food and Drug Administration has
classified the Pluvicto drug shortage status as resolved, and that
supply availability should continue to increase into 2024.
Pluvicto is an intravenous radioligand therapy approved in the
U.S., the EU and other countries to treat adults with advanced
prostate cancer who have already been treated with other
anti-cancer treatments.
"We have been working hard to increase the capacity and improve
the reliability of the supply of our radioligand therapies to
ensure patients have access to this therapy and to prepare for
future growth as more patients may become eligible for this
treatment," said Victor Bulto, president of Novartis U.S.
The Swiss pharmaceutical giant said late on Thursday that weekly
production capacity has more than doubled since May and that it is
working to further expand production lines at its sites.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
October 27, 2023 01:30 ET (05:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2024 to May 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From May 2023 to May 2024